YaoShiBang 2026 H1 Revenue RMB10.283 Billion, Net Profit RMB109 Million, Up 47.1%
YaoShiBang reported 2026 first-half revenue of RMB10.283 billion, up 4.5% year-on-year, and net profit of RMB109 million, up 47.1%. Its first-launch brand business and own-brand transactions grew 18.6% and 30.4% respectively. Monthly paying buyers averaged 430,000 with a 94% payment rate, and sellable SKUs exceeded 4.3 million, up 9% from 2025. Self-operated revenue rose 5.3%, with on-time delivery at 97.4%. TCM decoction piece sales exceeded 20,000 tonnes, up about 10%. LeYaoshi customers grew about 10%.
YaoShiBang released its interim results on August 20, 2026. In the first half of 2026, the company achieved operating revenue of RMB10.283 billion, up 4.5% year-on-year; net profit of RMB109 million, up 47.1%. The transaction scale of its first-launch brand business reached RMB1.281 billion, up 18.6%, while its own-brand transaction scale was RMB1.111 billion, up 30.4%.
In platform business, as of the end of the reporting period, the average monthly active buyers were 460,000, with about 430,000 paying buyers per month, and the monthly payment rate remained stable at 94%. The platform's average monthly sellable SKUs exceeded 4.3 million, up 9% from the same period in 2025, covering categories such as chemical drugs, Chinese patent medicines, TCM decoction pieces, medical devices, and nourishing health products.
In self-operated business, the number of partner suppliers exceeded 12,000, and the on-time order delivery rate improved to 97.4%. Self-operated revenue increased 5.3% from the same period in 2025, with an average of 29 orders per paying buyer per month. The ratio of marketing and sales expenses to revenue narrowed.
In TCM business, the Jinfang standard expanded to 372 varieties, and the grade standard was updated to 1,266 items. One new cooperative production area each was added for Tianqi and Gouteng authentic medicinal materials. In the first half of 2026, total sales of TCM decoction pieces exceeded 20,000 tonnes, up about 10% year-on-year.
The own-brand LeYaoshi completed spot delivery of over 1,200 varieties, with the number of covered customers up about 10% from the same period in 2025. The first-launch brand business empowered upstream pharmaceutical companies through digital marketing solutions, covering market insights, precise targeting, and sales monitoring.
In digitalization, Zhangdianyi SaaS served over 81,000 pharmacies, with more than 7,000 added in the first half. Financial indicators: accounts payable turnover days were approximately 78.9 days, inventory turnover days about 37.5 days, accounts receivable turnover days about 2.4 days, cash conversion cycle approximately negative 39.1 days, and operating cash flow remained net inflow.